Biweekly TAS-102 With Bevacizumab for Metastatic Colorectal Cancer Refractory to Standard Therapies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase Ib/II Study of Biweekly TAS-102 in Combination With Bevacizumab for Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
Oncologist 2020 Jul 14;[EPub Ahead of Print], H Satake, T Kato, K Oba, M Kotaka, Y Kagawa, H Yasui, M Nakamura, T Watanabe, T Matsumoto, T Kii, T Terazawa, A Makiyama, N Takano, M Yokota, Y Okita, K Matoba, H Hasegawa, A Tsuji, Y Komatsu, T Yoshino, K Yamazaki, H Mishima, E Oki, N Nagata, J SakamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.